Compare GSK plc (GSK) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ABRDN Physical Gold Shares ETF — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while ABRDN Physical Gold Shares ETF trades at $39.93 (market cap $7.03B). The key difference: GSK plc is far larger — about 13.1× ABRDN Physical Gold Shares ETF's market cap, and GSK plc pays a 3.9% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| GSK | SGOL | |
|---|---|---|
Market Cap | $91.88B | $7.03B |
Volume | 7,730,529 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $61.18 | $51.41 |
52-Week Low | $43.24 | $37.54 |
Typical Hold Time | 93 Days | 57 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
SGOL trades at $39.94, up 2.36% with a bearish technical outlook showing 17 sell signals versus 2 buy signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent softer inflation data provided some support. Moving averages indicate strong bearish momentum while oscillators remain neutral, suggesting potential consolidation near current levels.
The outlook remains cautious with technical indicators favoring downside momentum, though oversold conditions could provide near-term support. Key risks include persistent inflation concerns and Fed policy uncertainty, while potential catalysts include geopolitical tensions and sustained gold demand from China. Investors should monitor Treasury yield movements and inflation data for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
